Canopy Growth Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended March 31, 2022; comparisons are primarily with the year ended March 31, 2021. The filing is an annual report, not a standalone “2021 Q4” report. Amounts are Canadian dollars unless stated otherwise.
Business context
Canopy Growth produces and sells cannabis and cannabinoid products, alongside consumer products including Storz & Bickel vaporizers, This Works wellness products and BioSteel sports nutrition. Its reportable segments are global cannabis and other consumer products. Core markets include Canada, the United States and Germany. U.S. THC expansion remains contingent on federal permissibility; current U.S. consumer products include hemp-derived CBD products.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net revenue | $520.3 million | $546.6 million |
| Gross margin | $(193.1) million; (37%) | $67.0 million; 12% |
| Operating loss | $(1,082.7) million | $(1,243.5) million |
| Net loss | $(320.5) million | $(1,670.8) million |
| Adjusted EBITDA loss | $(415.4) million | $(340.3) million |
| Cash used in operating activities | $(545.8) million | $(465.7) million |
| Free cash flow | $(582.5) million | $(630.2) million |
Net loss attributable to Canopy Growth shareholders was $302.2 million, or $0.77 per share, versus a $1.745 billion loss, or $4.69 per share, in FY2021. The much smaller reported net loss largely reflected non-cash fair-value gains, rather than improved underlying operating performance. Adjusted EBITDA loss widened by 22%.
Global cannabis revenue fell 11% to $337.2 million; other consumer products revenue rose 9% to $183.1 million, supported mainly by BioSteel. Canadian recreational revenue declined 11% to $205.3 million, and Canadian medical revenue declined 5% to $52.6 million. Total revenue fell 5%. Gross margin deteriorated sharply, principally due to inventory write-downs, restructuring charges, price compression and lower cannabis-segment margins. The cannabis segment’s gross margin was (75%); other consumer products’ gross margin was 32%.
At March 31, 2022, cash and cash equivalents were $776.0 million and short-term investments were $595.7 million, down from a combined $2.299 billion a year earlier. Management stated that available liquidity, including undrawn credit capacity, was sufficient for at least the next 12 months. Total debt carrying value was approximately $1.501 billion, including a US$750 million secured term facility due March 2026, with interest at LIBOR plus 8.50% (1.00% floor), and $600 million principal of 4.25% convertible notes due July 2023. The credit facility requires minimum quarterly liquidity of US$200 million and is secured by substantially all borrower and guarantor assets.
Material changes and unusual items
- FY2022 gross margin included $123.7 million of inventory write-downs and other restructuring-related charges in cost of goods sold. Inventory write-downs across the year totaled $237.1 million.
- Total restructuring, impairment and related costs were $496.6 million. These included $224.7 million of property and equipment impairment/abandonment, $40.7 million of goodwill impairment and $26.1 million of other intangible-asset impairment. Goodwill impairment affected KeyLeaf and This Works.
- Other income was $753.3 million, versus other expense of $387.9 million in FY2021. The change was driven mainly by non-cash fair-value movements in the Acreage arrangement, CBI warrant liability and convertible notes as Canopy’s share price fell; fair-value changes on other investments partly offset those gains. These items materially influenced reported net loss.
- The January 2022 C3 divestiture generated $128.3 million cash proceeds, with potential earnout consideration of up to €42.6 million subject to milestones.
- Canopy acquired Supreme Cannabis and Ace Valley in FY2022. Supreme contributed $36.0 million of FY2022 revenue alongside Ace Valley; the acquisitions added brands and production capacity.
- Cash used in operations increased to $545.8 million. Investing activities provided $230.8 million, including proceeds from divestitures and short-term investment redemptions; financing activities used $45.5 million, mainly for debt repayment.
Outlook, commentary and risks
Management described a focus on execution, cost reduction and improving profitability, stating that it was aligning capacity and costs with market demand and targeting profitability over the medium term. No specific revenue, earnings or margin guidance was provided. The company announced further restructuring actions on April 26, 2022, including a planned reduction of approximately 250 full-time positions; expected savings and benefits are uncertain.
Management cited competitive pressure and price compression in Canadian cannabis, shifting consumer preferences, excess inventory, supply constraints in some product categories, and competition affecting medical and German cannabis sales. Other key risks include continuing operating losses and negative operating cash flow, potential additional impairments, dependence on licenses and evolving cannabis/CBD regulation, U.S. federal illegality of THC cannabis, product safety and recall exposure, COVID-19 and supply-chain disruption, and the possibility that liquidity, refinancing or covenant requirements could constrain operations.
U.S. acquisitions remain conditional: the Acreage arrangement and Wana purchase option depend on a defined U.S. federal-law Triggering Event. Canopy holds no current economic or voting interest in Wana under the option structure. The May 2022 Jetty agreements are also conditional and involve planned upfront consideration primarily in Canopy shares. Constellation Brands and affiliates held approximately 35.3% of Canopy’s common shares as of May 26, 2022, with warrants and convertible notes that could increase that ownership to approximately 52.3% if fully exercised or converted.
The auditor issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. The audit identified fair-value measurement of the Acreage financial instrument as a critical audit matter because it depends on significant unobservable assumptions.
Investor verification priorities
- Reconcile ongoing operating performance with reported net loss: assess the recurring cash impact of the $753.3 million other-income item and the $415.4 million Adjusted EBITDA loss.
- Review inventory quality, demand assumptions and the likelihood of further write-downs, given $237.1 million of FY2022 inventory write-downs and continued price pressure.
- Test liquidity against cash burn, the US$200 million minimum-liquidity covenant, the US$750 million secured facility’s variable rate and the July 2023 convertible-note maturity.
- Evaluate whether restructuring and capacity changes can improve gross margins without harming sales, and track the costs and execution of the announced 250-position reduction.
- Check the assumptions underlying goodwill and other fair values, especially the cannabis operations goodwill cushion of only about 5%–10% and the Acreage instrument’s legalization and share-price assumptions.
- Monitor progress and potential dilution from the Acreage, Wana and Jetty arrangements, as well as Constellation’s governance rights and potential ownership increase.
- Track the status and potential exposure of the disclosed class-action matters, including the proposed Canadian product-labeling case seeking aggregate damages against multiple defendants.